<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168425</url>
  </required_header>
  <id_info>
    <org_study_id>OSMUNDSS04192017181235</org_study_id>
    <nct_id>NCT03168425</nct_id>
  </id_info>
  <brief_title>Opioid Prescribing After Cesarean Delivery</brief_title>
  <official_title>A Randomized Controlled Trial to Improve Discharge Opioid Prescribing After Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The number of opioid overdose deaths in the United States has quadrupled in 15 years, a
      dramatic manifestation of the current opioid abuse epidemic. This rise parallels a sharp
      increase in the amount of legal prescription opioids dispensed. The abundance of prescription
      opioids available is a primary pathway for opioid abuse and diversion. Adjusting post-
      cesarean delivery opioid prescribing practices to better match actual patient need has the
      potential to reduce unused opioids available for diversion, nonmedical use, and development
      of chronic dependence, as well as reduce wasted resources.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary data from a quality improvement project performed in our department found that
      most women are prescribed opioids after discharge that were significantly in excess of the
      actual opioids used. However there is a subset of women (~25%) who use all opioids and
      complain that they were not prescribed enough. The only variable predictive of post-
      discharge opioid use was Inpatient opioid use. These data were used to develop a formula for
      estimating outpatient use based on inpatient use. Currently there are no guidelines for
      outpatient prescribing either at our institution or on a national level. On average, most
      patients at our institution received 30 tablets of 5mg oxycodone at discharge. In surveying
      providers, very few looked at inpatient use and most had a standard prescription that they
      gave everyone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Actual">September 21, 2017</completion_date>
  <primary_completion_date type="Actual">September 21, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants were randomized to either a personalized prescribing algorithm based off of inpatient opioid use versus standard discharge opioid prescribing.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unused Opioids</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>oxycodone 5mg tablet leftover from prescription at discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain: Frequency That Participants Reported Uncontrolled Pain</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Frequency that participants reported uncontrolled pain
Pain scores were examined based on how many negative responses indicating worse pain were reported to the five questions relating to analgesic adequacy. Thus participants could have a score that ranged from 0 to 5.
Question 1 - I was discharged with too few opioid pills (Yes=1, No=0) Question 2 - Overall, my pain is poorly controlled by these medications (Yes=1, No=0) Question 3 - Overall, my pain from delivery has been worse than expected (Yes=1, No=0) Question 4 - Pain interfered significantly with my ability to do normal activities (Yes=1, No=0) Question 5 - Since discharge, I needed more opioid than what was expected (Yes=1, No=0)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Surgery</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Tailored</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be prescribed an opioid based on a formula derived from inpatient opioid use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tailored prescription</intervention_name>
    <description>Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use</description>
    <arm_group_label>Tailored</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Participants will be prescribed 30 tablets of oxycodone 5mg</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women 18-50 years old

          -  Women undergoing cesarean delivery at a single institution

        Exclusion Criteria:

          -  Major post-surgical complications: cesarean hysterectomy, bowl or bladder injury,
             reoperation, ICU admission, wound infection or separation

          -  Chronic opioid use: Taking buprenorphine during pregnancy, taking an opioid for &gt; 7
             days during pregnancy.

          -  Non English or Spanish speaking
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postpartum women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sarah Osmundson</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <results_first_submitted>September 21, 2018</results_first_submitted>
  <results_first_submitted_qc>February 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2019</results_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Sarah Osmundson</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>safe opioid prescribing</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03168425/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tailored</title>
          <description>Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
Tailored prescription: Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
Control: Participants will be prescribed 30 tablets of oxycodone 5mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unable to confirm post op opioids</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tailored</title>
          <description>Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
Tailored prescription: Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
Control: Participants will be prescribed 30 tablets of oxycodone 5mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="190"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>7 tailored/ 11 control subjects lost to follow-up</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="87"/>
                    <count group_id="B2" value="85"/>
                    <count group_id="B3" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.4" spread="5.9"/>
                    <measurement group_id="B2" value="30.4" spread="5.8"/>
                    <measurement group_id="B3" value="30.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>7 Tailored/ 11 control subjects lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="87"/>
                    <count group_id="B2" value="85"/>
                    <count group_id="B3" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>11 Tailored/ 7 control subjects were lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="87"/>
                    <count group_id="B2" value="85"/>
                    <count group_id="B3" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>7 Tailored/ 11 Control subjects lost to follow-up</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="87"/>
                    <count group_id="B2" value="85"/>
                    <count group_id="B3" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Unused Opioids</title>
        <description>oxycodone 5mg tablet leftover from prescription at discharge</description>
        <time_frame>4 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tailored</title>
            <description>Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
Participants who received an individualized prescription were discharged with 14 [interquartile range 12â€“16] oxycodone 5mg tablets.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
Control: Participants will be prescribed 30 tablets of oxycodone 5mg</description>
          </group>
        </group_list>
        <measure>
          <title>Unused Opioids</title>
          <description>oxycodone 5mg tablet leftover from prescription at discharge</description>
          <units>oxycodone 5mg tablets</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain: Frequency That Participants Reported Uncontrolled Pain</title>
        <description>Frequency that participants reported uncontrolled pain
Pain scores were examined based on how many negative responses indicating worse pain were reported to the five questions relating to analgesic adequacy. Thus participants could have a score that ranged from 0 to 5.
Question 1 - I was discharged with too few opioid pills (Yes=1, No=0) Question 2 - Overall, my pain is poorly controlled by these medications (Yes=1, No=0) Question 3 - Overall, my pain from delivery has been worse than expected (Yes=1, No=0) Question 4 - Pain interfered significantly with my ability to do normal activities (Yes=1, No=0) Question 5 - Since discharge, I needed more opioid than what was expected (Yes=1, No=0)</description>
        <time_frame>4 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tailored</title>
            <description>Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
Tailored prescription: Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
Control: Participants will be prescribed 30 tablets of oxycodone 5mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pain: Frequency That Participants Reported Uncontrolled Pain</title>
          <description>Frequency that participants reported uncontrolled pain
Pain scores were examined based on how many negative responses indicating worse pain were reported to the five questions relating to analgesic adequacy. Thus participants could have a score that ranged from 0 to 5.
Question 1 - I was discharged with too few opioid pills (Yes=1, No=0) Question 2 - Overall, my pain is poorly controlled by these medications (Yes=1, No=0) Question 3 - Overall, my pain from delivery has been worse than expected (Yes=1, No=0) Question 4 - Pain interfered significantly with my ability to do normal activities (Yes=1, No=0) Question 5 - Since discharge, I needed more opioid than what was expected (Yes=1, No=0)</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tailored</title>
          <description>Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
Tailored prescription: Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
Control: Participants will be prescribed 30 tablets of oxycodone 5mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Surgical Site Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sarah Osmundson, MD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>+1 (615) 343-5700</phone>
      <email>sarah.osmundson@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

